-
2
-
-
84855955174
-
Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC)
-
Klastersky J, Awada A. Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol. 2012; 81:49-57.
-
(2012)
Crit Rev Oncol Hematol
, vol.81
, pp. 49-57
-
-
Klastersky, J1
Awada, A.2
-
3
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361:947-957.
-
(2009)
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, TS1
Wu, YL2
Thongprasert, S3
Yang, CH4
Chu, DT5
Saijo, N6
Sunpaweravong, P7
Han, B8
Margono, B9
Ichinose, Y10
Nishiwaki, Y11
Ohe, Y12
Yang, JJ13
-
4
-
-
79960889662
-
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
-
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12:735-742.
-
(2011)
Lancet Oncol
, vol.12
, pp. 735-742
-
-
Zhou, C1
Wu, YL2
Chen, G3
Feng, J4
Liu, XQ5
Wang, C6
Zhang, S7
Wang, J8
Zhou, S9
Ren, S10
Lu, S11
Zhang, L12
Hu, C13
-
5
-
-
84884736973
-
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
-
Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31:3327-3334.
-
(2013)
J Clin Oncol
, vol.31
, pp. 3327-3334
-
-
Sequist, LV1
Yang, JC2
Yamamoto, N3
O'Byrne, K4
Hirsh, V5
Mok, T6
Geater, SL7
Orlov, S8
Tsai, CM9
Boyer, M10
Su, WC11
Bennouna, J12
Kato, T13
-
6
-
-
84879071011
-
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
-
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368:2385-2394.
-
(2013)
N Engl J Med
, vol.368
, pp. 2385-2394
-
-
Shaw, AT1
Kim, DW2
Nakagawa, K3
Seto, T4
Crinó, L5
Ahn, MJ6
De Pas, T7
Besse, B8
Solomon, BJ9
Blackhall, F10
Wu, YL11
Thomas, M12
O'Byrne, KJ13
-
7
-
-
84976285844
-
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
-
Wang J, Wang B, Chu H, Yao Y. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther. 2016; 9:3711-3726.
-
(2016)
Onco Targets Ther
, vol.9
, pp. 3711-3726
-
-
Wang, J1
Wang, B2
Chu, H3
Yao, Y.4
-
8
-
-
84857882376
-
Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?
-
Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther. 2012; 13:247-263.
-
(2012)
Cancer Biol Ther
, vol.13
, pp. 247-263
-
-
Aggarwal, C1
Somaiah, N2
Simon, G.3
-
9
-
-
79952284127
-
Hallmarks of cancer: the next generation
-
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D1
Weinberg, RA.2
-
10
-
-
0035432151
-
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy
-
Blagosklonny MV. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy. Int J Oncol. 2001; 19:257-262.
-
(2001)
Int J Oncol
, vol.19
, pp. 257-262
-
-
Blagosklonny, MV.1
-
11
-
-
84859415553
-
Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer
-
Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012; 18:1855-1862.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 1855-1862
-
-
Brooks, AN1
Kilgour, E2
Smith, PD.3
-
12
-
-
0345798150
-
Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors
-
Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest. 2003, 112:1142-1151.
-
(2003)
J Clin Invest
, vol.112
, pp. 1142-1151
-
-
Abramsson, A1
Lindblom, P2
Betsholtz, C.3
-
13
-
-
63749125392
-
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
-
Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009; 21:154-165.
-
(2009)
Curr Opin Cell Biol
, vol.21
, pp. 154-165
-
-
Lohela, M1
Bry, M2
Tammela, T3
Alitalo, K.4
-
14
-
-
0030996171
-
Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study
-
Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA, Bevilacqua G. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst. 1997; 89:881-886.
-
(1997)
J Natl Cancer Inst
, vol.89
, pp. 881-886
-
-
Fontanini, G1
Lucchi, M2
Vignati, S3
Mussi, A4
Ciardiello, F5
De Laurentiis, M6
De Placido, S7
Basolo, F8
Angeletti, CA9
Bevilacqua, G.10
-
15
-
-
0030668890
-
Tumor angiogenesis and biologic markers in resected stage I NSCLC
-
Lucchi M, Fontanini G, Mussi A, Vignati S, Ribechini A, Menconi GF, Bevilacqua G, Angeletti CA. Tumor angiogenesis and biologic markers in resected stage I NSCLC. Eur J Cardiothorac Surg. 1997; 12:535-541.
-
(1997)
Eur J Cardiothorac Surg
, vol.12
, pp. 535-541
-
-
Lucchi, M1
Fontanini, G2
Mussi, A3
Vignati, S4
Ribechini, A5
Menconi, GF6
Bevilacqua, G7
Angeletti, CA.8
-
16
-
-
1642472018
-
Antiangiogenic therapy and tumor progression
-
Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004; 5:13-17.
-
(2004)
Cancer Cell
, vol.5
, pp. 13-17
-
-
Blagosklonny, MV.1
-
17
-
-
33747855481
-
Comparing antibody and small-molecule therapies for cancer
-
Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006; 6:714-727.
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 714-727
-
-
Imai, K1
Takaoka, A.2
-
18
-
-
2942657615
-
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
-
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004; 22:2184-2191.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2184-2191
-
-
Johnson, DH1
Fehrenbacher, L2
Novotny, WF3
Herbst, RS4
Nemunaitis, JJ5
Jablons, DM6
Langer, CJ7
DeVore, RF8
Gaudreault, J9
Damico, LA10
Holmgren, E11
Kabbinavar, F.12
-
19
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355:2542-2550.
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A1
Gray, R2
Perry, MC3
Brahmer, J4
Schiller, JH5
Dowlati, A6
Lilenbaum, R7
Johnson, DH.8
-
20
-
-
62449124416
-
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil
-
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009; 27:1227-1234.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1227-1234
-
-
Reck, M1
von Pawel, J2
Zatloukal, P3
Ramlau, R4
Gorbounova, V5
Hirsh, V6
Leighl, N7
Mezger, J8
Archer, V9
Moore, N10
Manegold, C.11
-
21
-
-
77951473661
-
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
-
BO17704 Study Group
-
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010; 21:1804-1809.
-
(2010)
Ann Oncol
, vol.21
, pp. 1804-1809
-
-
Reck, M1
von Pawel, J2
Zatloukal, P3
Ramlau, R4
Gorbounova, V5
Hirsh, V6
Leighl, N7
Mezger, J8
Archer, V9
Moore, N10
Manegold, C.11
-
22
-
-
84860505684
-
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced nonsquamous non-small-cell lung cancer
-
Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced nonsquamous non-small-cell lung cancer. Lung cancer. 2012; 76:362-367.
-
(2012)
Lung cancer
, vol.76
, pp. 362-367
-
-
Niho, S1
Kunitoh, H2
Nokihara, H3
Horai, T4
Ichinose, Y5
Hida, T6
Yamamoto, N7
Kawahara, M8
Shinkai, T9
Nakagawa, K10
Matsui, K11
Negoro, S12
Yokoyama, A13
-
23
-
-
84937117699
-
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/ Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer
-
2 et l
-
Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C2, Zhang H, et l. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/ Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33:2197-2204.
-
(2015)
J Clin Oncol
, vol.33
, pp. 2197-2204
-
-
Zhou, C1
Wu, YL2
Chen, G3
Liu, X4
Zhu, Y5
Lu, S6
Feng, J7
He, J8
Han, B9
Wang, J10
Jiang, G11
Hu, C12
Zhang, H13
-
24
-
-
77955268612
-
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
-
Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010; 11:733-740.
-
(2010)
Lancet Oncol
, vol.11
, pp. 733-740
-
-
Crinò, L1
Dansin, E2
Garrido, P3
Griesinger, F4
Laskin, J5
Pavlakis, N6
Stroiakovski, D7
Thatcher, N8
Tsai, CM9
Wu, YL10
Zhou, C.11
-
25
-
-
79958164295
-
Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study
-
Tsai CM, Au JS, Chang GC, Cheng AC, Zhou C, Wu YL. Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study. J Thorac Oncol. 2011; 6:1092-1097.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1092-1097
-
-
Tsai, CM1
Au, JS2
Chang, GC3
Cheng, AC4
Zhou, C5
Wu, YL.6
-
26
-
-
84900802283
-
Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study
-
Zhou CC, Bai CX, Guan ZZ, Jiang GL, Shi YK, Wang MZ, Wu YL, Zhang YP, Zhu YZ. Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study. Clin Transl Oncol. 2014; 16:463-468.
-
(2014)
Clin Transl Oncol
, vol.16
, pp. 463-468
-
-
Zhou, CC1
Bai, CX2
Guan, ZZ3
Jiang, GL4
Shi, YK5
Wang, MZ6
Wu, YL7
Zhang, YP8
Zhu, YZ.9
-
27
-
-
80052607351
-
Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis
-
Botrel TE, Clark O, Clark L, Paladini L, Faleiros E, Pegoretti B. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis. Lung cancer. 2011; 74:89-97.
-
(2011)
Lung cancer
, vol.74
, pp. 89-97
-
-
Botrel, TE1
Clark, O2
Clark, L3
Paladini, L4
Faleiros, E5
Pegoretti, B.6
-
28
-
-
84871538217
-
meta-analysis of bevacizumab in advanced NSCLC collaborative group. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
-
Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B, Pignon JP. meta-analysis of bevacizumab in advanced NSCLC collaborative group. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013; 24:20-30.
-
(2013)
Ann Oncol
, vol.24
, pp. 20-30
-
-
Soria, JC1
Mauguen, A2
Reck, M3
Sandler, AB4
Saijo, N5
Johnson, DH6
Burcoveanu, D7
Fukuoka, M8
Besse, B9
Pignon, JP.10
-
29
-
-
79955565439
-
Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network
-
Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschkus S. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. Oncologist. 2011; 16:486-496.
-
(2011)
Oncologist
, vol.16
, pp. 486-496
-
-
Nadler, E1
Yu, E2
Ravelo, A3
Sing, A4
Forsyth, M5
Gruschkus, S.6
-
30
-
-
84863084949
-
First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients
-
Leon L, Vazquez S, Gracia JM, Casal J, Lazaro M, Firvida JL, Amenedo M, Santome L, Macia S. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients. Expert Opin Pharmacother. 2012; 13:1389-1396.
-
(2012)
Expert Opin Pharmacother
, vol.13
, pp. 1389-1396
-
-
Leon, L1
Vazquez, S2
Gracia, JM3
Casal, J4
Lazaro, M5
Firvida, JL6
Amenedo, M7
Santome, L8
Macia, S.9
-
31
-
-
84868212372
-
Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer
-
Stevenson JP, Langer CJ, Somer RA, Evans TL, Rajagopalan K, Krieger K, Jacobs-Small M, Dyanick N, Milcarek B, Coakley S, Walker S, Eaby-Sandy B, Hageboutros A. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer. Cancer. 2012; 118:5580-5587.
-
(2012)
Cancer
, vol.118
, pp. 5580-5587
-
-
Stevenson, JP1
Langer, CJ2
Somer, RA3
Evans, TL4
Rajagopalan, K5
Krieger, K6
Jacobs-Small, M7
Dyanick, N8
Milcarek, B9
Coakley, S10
Walker, S11
Eaby-Sandy, B12
Hageboutros, A.13
-
32
-
-
70249116447
-
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer
-
Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009; 27: 3284-3289.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3284-3289
-
-
Patel, JD1
Hensing, TA2
Rademaker, A3
Hart, EM4
Blum, MG5
Milton, DT6
Bonomi, PD.7
-
33
-
-
84886385462
-
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089)
-
Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013; 31:3004-3011.
-
(2013)
J Clin Oncol
, vol.31
, pp. 3004-3011
-
-
Barlesi, F1
Scherpereel, A2
Rittmeyer, A3
Pazzola, A4
Ferrer Tur, N5
Kim, JH6
Ahn, MJ7
Aerts, JG8
Gorbunova, V9
Vikström, A10
Wong, EK11
Perez-Moreno, P12
Mitchell, L13
-
34
-
-
84905822586
-
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
-
Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014; 25:1044-1052.
-
(2014)
Ann Oncol
, vol.25
, pp. 1044-1052
-
-
Barlesi, F1
Scherpereel, A2
Gorbunova, V3
Gervais, R4
Vikström, A5
Chouaid, C6
Chella, A7
Kim, JH8
Ahn, MJ9
Reck, M10
Pazzola, A11
Kim, HT12
Aerts, JG13
-
35
-
-
84892454962
-
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer
-
Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013; 31:4349-4357.
-
(2013)
J Clin Oncol
, vol.31
, pp. 4349-4357
-
-
Patel, JD1
Socinski, MA2
Garon, EB3
Reynolds, CH4
Spigel, DR5
Olsen, MR6
Hermann, RC7
Jotte, RM8
Beck, T9
Richards, DA10
Guba, SC11
Liu, J12
Frimodt-Moller, B13
-
36
-
-
84926419605
-
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer
-
Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015; 10:134-142.
-
(2015)
J Thorac Oncol
, vol.10
, pp. 134-142
-
-
Zinner, RG1
Obasaju, CK2
Spigel, DR3
Weaver, RW4
Beck, JT5
Waterhouse, DM6
Modiano, MR7
Hrinczenko, B8
Nikolinakos, PG9
Liu, J10
Koustenis, AG11
Winfree, KB12
Melemed, SA13
-
37
-
-
36048982143
-
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer
-
Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007; 25:4743-4750.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4743-4750
-
-
Herbst, RS1
O'Neill, VJ2
Fehrenbacher, L3
Belani, CP4
Bonomi, PD5
Hart, L6
Melnyk, O7
Ramies, D8
Lin, M9
Sandler, A.10
-
38
-
-
80155141305
-
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial
-
Gridelli C, Bennouna J, de Castro J, Dingemans AM, Griesinger F, Grossi F, Rossi A, Thatcher N, Wong EK, Langer C. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Clin Lung Cancer. 2011; 12:407-411.
-
(2011)
Clin Lung Cancer
, vol.12
, pp. 407-411
-
-
Gridelli, C1
Bennouna, J2
de Castro, J3
Dingemans, AM4
Griesinger, F5
Grossi, F6
Rossi, A7
Thatcher, N8
Wong, EK9
Langer, C.10
-
39
-
-
84908139963
-
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
-
Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15:1224-1235.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1224-1235
-
-
Wilke, H1
Muro, K2
Van Cutsem, E3
Oh, SC4
Bodoky, G5
Shimada, Y6
Hironaka, S7
Sugimoto, N8
Lipatov, O9
Kim, TY10
Cunningham, D11
Rougier, P12
Komatsu, Y13
-
40
-
-
84933673498
-
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
-
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015; 16:499-508.
-
(2015)
Lancet Oncol
, vol.16
, pp. 499-508
-
-
Tabernero, J1
Yoshino, T2
Cohn, AL3
Obermannova, R4
Bodoky, G5
Garcia-Carbonero, R6
Ciuleanu, TE7
Portnoy, DC8
Van Cutsem, E9
Grothey, A10
Prausová, J11
Garcia-Alfonso, P12
Yamazaki, K13
-
41
-
-
84925706983
-
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/ IV non-small-cell lung cancer
-
Camidge DR, Berge EM, Doebele RC, Ballas MS, Jahan T, Haigentz M Jr, Hoffman D, Spicer J, West H, Lee P, Yang L, Joshi A, Gao L, et al. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/ IV non-small-cell lung cancer. J Thorac Oncol. 2014; 9:1532-1539.
-
(2014)
J Thorac Oncol
, vol.9
, pp. 1532-1539
-
-
Camidge, DR1
Berge, EM2
Doebele, RC3
Ballas, MS4
Jahan, T5
Haigentz, M6
Hoffman, D7
Spicer, J8
West, H9
Lee, P10
Yang, L11
Joshi, A12
Gao, L13
-
42
-
-
84924207092
-
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer
-
Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J Jr, Cao D, Alexandris E, Yurasov S, Camidge DR, et al. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015; 121:883-892.
-
(2015)
Cancer
, vol.121
, pp. 883-892
-
-
Doebele, RC1
Spigel, D2
Tehfe, M3
Thomas, S4
Reck, M5
Verma, S6
Eakle, J7
Bustin, F8
Goldschmidt, J9
Cao, D10
Alexandris, E11
Yurasov, S12
Camidge, DR13
-
43
-
-
84906903314
-
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
-
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384:665-673.
-
(2014)
Lancet
, vol.384
, pp. 665-673
-
-
Garon, EB1
Ciuleanu, TE2
Arrieta, O3
Prabhash, K4
Syrigos, KN5
Goksel, T6
Park, K7
Gorbunova, V8
Kowalyszyn, RD9
Pikiel, J10
Czyzewicz, G11
Orlov, SV12
Lewanski, CR13
-
44
-
-
84978802703
-
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
-
Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, Nishio M, Ohe Y, Koue T, Nakamura T, Enatsu S, Lee P, Ferry D, et al. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung cancer. 2016; 99:186-193.
-
(2016)
Lung cancer
, vol.99
, pp. 186-193
-
-
Yoh, K1
Hosomi, Y2
Kasahara, K3
Yamada, K4
Takahashi, T5
Yamamoto, N6
Nishio, M7
Ohe, Y8
Koue, T9
Nakamura, T10
Enatsu, S11
Lee, P12
Ferry, D13
-
45
-
-
80051638135
-
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer
-
Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29:2965-2971.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2965-2971
-
-
Lara, PN1
Douillard, JY2
Nakagawa, K3
von Pawel, J4
McKeage, MJ5
Albert, I6
Losonczy, G7
Reck, M8
Heo, DS9
Fan, X10
Fandi, A11
Scagliotti, G.12
-
46
-
-
84867602821
-
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial
-
Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, Baldotto C, Bennouna J, Shepherd FA, Le-Guennec S, Rey A, Miller V, Thatcher N, et al. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol. 2012; 30:3640-3647.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3640-3647
-
-
Ramlau, R1
Gorbunova, V2
Ciuleanu, TE3
Novello, S4
Ozguroglu, M5
Goksel, T6
Baldotto, C7
Bennouna, J8
Shepherd, FA9
Le-Guennec, S10
Rey, A11
Miller, V12
Thatcher, N13
-
47
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359:378-390.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, JM1
Ricci, S2
Mazzaferro, V3
Hilgard, P4
Gane, E5
Blanc, JF6
de Oliveira, AC7
Santoro, A8
Raoul, JL9
Forner, A10
Schwartz, M11
Porta, C12
Zeuzem, S13
-
48
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
-
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10:25-34.
-
(2009)
Lancet Oncol
, vol.10
, pp. 25-34
-
-
Cheng, AL1
Kang, YK2
Chen, Z3
Tsao, CJ4
Qin, S5
Kim, JS6
Luo, R7
Feng, J8
Ye, S9
Yang, TS10
Xu, J11
Sun, Y12
Liang, H13
-
49
-
-
77951639655
-
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer
-
Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller A, Arén O, Csollak M, Albert I, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28:1835-1842.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1835-1842
-
-
Scagliotti, G1
Novello, S2
von Pawel, J3
Reck, M4
Pereira, JR5
Thomas, M6
Abrão Miziara, JE7
Balint, B8
De Marinis, F9
Keller, A10
Arén, O11
Csollak, M12
Albert, I13
-
50
-
-
84865721505
-
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/ cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer
-
Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, Zhang L, Liao M, Sun Y, Gans S, Syrigos K, Le Marie E, Gottfried M, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/ cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol. 2012; 30:3084-3092.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3084-3092
-
-
Paz-Ares, LG1
Biesma, B2
Heigener, D3
von Pawel, J4
Eisen, T5
Bennouna, J6
Zhang, L7
Liao, M8
Sun, Y9
Gans, S10
Syrigos, K11
Le Marie, E12
Gottfried, M13
-
51
-
-
84865095318
-
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/ paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer: MONET1
-
Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/ paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer: MONET1. J Clin Oncol. 2012; 30:2829-2836.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2829-2836
-
-
Scagliotti, GV1
Vynnychenko, I2
Park, K3
Ichinose, Y4
Kubota, K5
Blackhall, F6
Pirker, R7
Galiulin, R8
Ciuleanu, TE9
Sydorenko, O10
Dediu, M11
Papai-Szekely, Z12
Banaclocha, NM13
-
52
-
-
79955795090
-
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
-
Blumenschein GR Jr, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011; 22:2057-2067.
-
(2011)
Ann Oncol
, vol.22
, pp. 2057-2067
-
-
Blumenschein, GR1
Kabbinavar, F2
Menon, H3
Mok, TS4
Stephenson, J5
Beck, JT6
Lakshmaiah, K7
Reckamp, K8
Hei, YJ9
Kracht, K10
Sun, YN11
Sikorski, R12
Schwartzberg, L.13
-
53
-
-
42949105645
-
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group
-
Laurie SA, Gauthier I, Arnold A, Shepherd FA, Ellis PM, Chen E, Goss G, Powers J, Walsh W, Tu D, Robertson J, Puchalski TA, Seymour L. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 2008; 26:1871-1878.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1871-1878
-
-
Laurie, SA1
Gauthier, I2
Arnold, A3
Shepherd, FA4
Ellis, PM5
Chen, E6
Goss, G7
Powers, J8
Walsh, W9
Tu, D10
Robertson, J11
Puchalski, TA12
Seymour, L.13
-
54
-
-
73949092851
-
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study
-
Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol. 2010; 28:49-55.
-
(2010)
J Clin Oncol
, vol.28
, pp. 49-55
-
-
Goss, GD1
Arnold, A2
Shepherd, FA3
Dediu, M4
Ciuleanu, TE5
Fenton, D6
Zukin, M7
Walde, D8
Laberge, F9
Vincent, MD10
Ellis, PM11
Laurie, SA12
Ding, K13
-
55
-
-
84894041073
-
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29
-
Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, et al. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer. 2014; 50:706-712.
-
(2014)
Eur J Cancer
, vol.50
, pp. 706-712
-
-
Laurie, SA1
Solomon, BJ2
Seymour, L3
Ellis, PM4
Goss, GD5
Shepherd, FA6
Boyer, MJ7
Arnold, AM8
Clingan, P9
Laberge, F10
Fenton, D11
Hirsh, V12
Zukin, M13
-
56
-
-
84871977845
-
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528
-
Dy GK, Mandrekar SJ, Nelson GD, Meyers JP, Adjei AA, Ross HJ, Ansari RH, Lyss AP, Stella PJ, Schild SE, Molina JR, Adjei AA. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. J Thorac Oncol. 2013; 8:79-88.
-
(2013)
J Thorac Oncol
, vol.8
, pp. 79-88
-
-
Dy, GK1
Mandrekar, SJ2
Nelson, GD3
Meyers, JP4
Adjei, AA5
Ross, HJ6
Ansari, RH7
Lyss, AP8
Stella, PJ9
Schild, SE10
Molina, JR11
Adjei, AA.12
-
57
-
-
56749102822
-
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer
-
Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008; 26:5407-5415.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5407-5415
-
-
Heymach, JV1
Paz-Ares, L2
De Braud, F3
Sebastian, M4
Stewart, DJ5
Eberhardt, WE6
Ranade, AA7
Cohen, G8
Trigo, JM9
Sandler, AB10
Bonomi, PD11
Herbst, RS12
Krebs, AD13
-
58
-
-
84857838650
-
Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent nonsmall cell lung cancer (NSCLC): PrECOG PrE0501 update on maintenance treatment, progression-free survival (PFS), and overall survival (OS)
-
Aisner J, Manola J, Dakhil SR, Stella PJ, Schiller JH. Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent nonsmall cell lung cancer (NSCLC): PrECOG PrE0501 update on maintenance treatment, progression-free survival (PFS), and overall survival (OS). J Clin Oncol. 2011; 29:7560.
-
(2011)
J Clin Oncol
, vol.29
, pp. 7560
-
-
Aisner, J1
Manola, J2
Dakhil, SR3
Stella, PJ4
Schiller, JH.5
-
59
-
-
84892165925
-
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer
-
Scagliotti GV, Felip E, Besse B, von Pawel J, Mellemgaard A, Reck M, Bosquee L, Chouaid C, Lianes-Barragán P, Paul EM, Ruiz-Soto R, Sigal E, Ottesen LH, et al. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. J Thorac Oncol. 2013; 8:1529-1537.
-
(2013)
J Thorac Oncol
, vol.8
, pp. 1529-1537
-
-
Scagliotti, GV1
Felip, E2
Besse, B3
von Pawel, J4
Mellemgaard, A5
Reck, M6
Bosquee, L7
Chouaid, C8
Lianes-Barragán, P9
Paul, EM10
Ruiz-Soto, R11
Sigal, E12
Ottesen, LH13
-
60
-
-
84900002806
-
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for nonsquamous non-small-cell lung cancer
-
Belani CP, Yamamoto N, Bondarenko IM, Poltoratskiy A, Novello S, Tang J, Bycott P, Niethammer AG, Ingrosso A, Kim S, Scagliotti GV. Randomized phase II study of pemetrexed/cisplatin with or without axitinib for nonsquamous non-small-cell lung cancer. BMC cancer. 2014; 14:290.
-
(2014)
BMC cancer
, vol.14
, pp. 290
-
-
Belani, CP1
Yamamoto, N2
Bondarenko, IM3
Poltoratskiy, A4
Novello, S5
Tang, J6
Bycott, P7
Niethammer, AG8
Ingrosso, A9
Kim, S10
Scagliotti, GV.11
-
61
-
-
84895480028
-
Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer
-
Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, et al. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol. 2014; 25:132-138.
-
(2014)
Ann Oncol
, vol.25
, pp. 132-138
-
-
Twelves, C1
Chmielowska, E2
Havel, L3
Popat, S4
Swieboda-Sadlej, A5
Sawrycki, P6
Bycott, P7
Ingrosso, A8
Kim, S9
Williams, JA10
Chen, C11
Olszanski, AJ12
de Besi, P13
-
62
-
-
84922341727
-
Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer
-
Ramalingam SS, Shtivelband M, Soo RA, Barrios CH, Makhson A, Segalla JG, Pittman KB, Kolman P, Pereira JR, Srkalovic G, Belani CP, Axelrod R, Owonikoko TK, et al. Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015; 33:433-441.
-
(2015)
J Clin Oncol
, vol.33
, pp. 433-441
-
-
Ramalingam, SS1
Shtivelband, M2
Soo, RA3
Barrios, CH4
Makhson, A5
Segalla, JG6
Pittman, KB7
Kolman, P8
Pereira, JR9
Srkalovic, G10
Belani, CP11
Axelrod, R12
Owonikoko, TK13
-
63
-
-
84857871901
-
A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study
-
Molina JR, Dy GK, Foster NR, Allen Ziegler KL, Adjei A, Rowland KM, Aubry M, Flynn PJ, Mandrekar SJ, Schild SE, Adjei AA. A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. J Clin Oncol. 2011; 29:7513.
-
(2011)
J Clin Oncol
, vol.29
, pp. 7513
-
-
Molina, JR1
Dy, GK2
Foster, NR3
Allen Ziegler, KL4
Adjei, A5
Rowland, KM6
Aubry, M7
Flynn, PJ8
Mandrekar, SJ9
Schild, SE10
Adjei, AA.11
-
64
-
-
84893413347
-
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer
-
Heist RS, Wang X, Hodgson L, Otterson GA, Stinchcombe TE, Gandhi L, Villalona-Calero MA, Watson P, Vokes EE, Socinski MA. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2014; 9:214-221.
-
(2014)
J Thorac Oncol
, vol.9
, pp. 214-221
-
-
Heist, RS1
Wang, X2
Hodgson, L3
Otterson, GA4
Stinchcombe, TE5
Gandhi, L6
Villalona-Calero, MA7
Watson, P8
Vokes, EE9
Socinski, MA.10
-
65
-
-
77954035012
-
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
-
Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010; 11:619-626.
-
(2010)
Lancet Oncol
, vol.11
, pp. 619-626
-
-
Herbst, RS1
Sun, Y2
Eberhardt, WE3
Germonpré, P4
Saijo, N5
Zhou, C6
Wang, J7
Li, L8
Kabbinavar, F9
Ichinose, Y10
Qin, S11
Zhang, L12
Biesma, B13
-
66
-
-
79952742483
-
Vandetanib plus pemetrexed for the second-line treatment of advanced nonsmall-cell lung cancer: a randomized, double-blind phase III trial
-
de Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced nonsmall-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011; 29:1067-1074.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1067-1074
-
-
de Boer, RH1
Arrieta, Ó2
Yang, CH3
Gottfried, M4
Chan, V5
Raats, J6
de Marinis, F7
Abratt, RP8
Wolf, J9
Blackhall, FH10
Langmuir, P11
Milenkova, T12
Read, J13
-
67
-
-
84892967581
-
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
-
Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15:143-155.
-
(2014)
Lancet Oncol
, vol.15
, pp. 143-155
-
-
Reck, M1
Kaiser, R2
Mellemgaard, A3
Douillard, JY4
Orlov, S5
Krzakowski, M6
von Pawel, J7
Gottfried, M8
Bondarenko, I9
Liao, M10
Gann, CN11
Barrueco, J12
Gaschler-Markefski, B13
-
68
-
-
84994609086
-
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
-
Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, Voccia I, Pawel JV, Kovcin V, Agulnik J, Gaschler-Markefski B, Barrueco J, Sikken P, et al. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Lung Cancer. 2016; 102:65-73.
-
(2016)
Lung Cancer
, vol.102
, pp. 65-73
-
-
Hanna, NH1
Kaiser, R2
Sullivan, RN3
Aren, OR4
Ahn, MJ5
Tiangco, B6
Voccia, I7
Pawel, JV8
Kovcin, V9
Agulnik, J10
Gaschler-Markefski, B11
Barrueco, J12
Sikken, P13
-
69
-
-
32344443105
-
China offers alternative gateway for experimental drugs
-
Jia H, Kling J. China offers alternative gateway for experimental drugs. Nat Biotechnol. 2006; 24:117-118.
-
(2006)
Nat Biotechnol
, vol.24
, pp. 117-118
-
-
Jia, H1
Kling, J.2
-
70
-
-
23944472880
-
Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients
-
[Article in Chinese]
-
Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K, Zhu Y, Zhou Q, Hou M, Guan Z, Li W, Zhuang W, Wang D, et al. [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. [Article in Chinese]. Zhongguo fei ai za zhi. 2005; 8:283-290.
-
(2005)
Zhongguo fei ai za zhi
, vol.8
, pp. 283-290
-
-
Wang, J1
Sun, Y2
Liu, Y3
Yu, Q4
Zhang, Y5
Li, K6
Zhu, Y7
Zhou, Q8
Hou, M9
Guan, Z10
Li, W11
Zhuang, W12
Wang, D13
-
71
-
-
79958178412
-
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer
-
Han B, Xiu Q, Wang H, Shen J, Gu A, Luo Y, Bai C, Guo S, Liu W, Zhuang Z, Zhang Y, Zhao Y, Jiang L, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol. 2011; 6:1104-1109.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1104-1109
-
-
Han, B1
Xiu, Q2
Wang, H3
Shen, J4
Gu, A5
Luo, Y6
Bai, C7
Guo, S8
Liu, W9
Zhuang, Z10
Zhang, Y11
Zhao, Y12
Jiang, L13
-
72
-
-
84865281099
-
Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer
-
Rong B, Yang S, Li W, Zhang W, Ming Z. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol. 2012; 10:170.
-
(2012)
World J Surg Oncol
, vol.10
, pp. 170
-
-
Rong, B1
Yang, S2
Li, W3
Zhang, W4
Ming, Z.5
-
73
-
-
84903985897
-
Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better
-
Di Maio M, Morabito A, Piccirillo MC, Daniele G, Giordano P, Costanzo R, Sandomenico C, Montanino A, Rocco G, Perrone F. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….Curr Pharm Des. 2014; 20:3901-3913.
-
(2014)
Curr Pharm Des
, vol.20
, pp. 3901-3913
-
-
Di Maio, M1
Morabito, A2
Piccirillo, MC3
Daniele, G4
Giordano, P5
Costanzo, R6
Sandomenico, C7
Montanino, A8
Rocco, G9
Perrone, F.10
-
74
-
-
0037341379
-
Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice
-
Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res. 2003; 9:1200-1210.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1200-1210
-
-
Kim, SJ1
Uehara, H2
Karashima, T3
Shepherd, DL4
Killion, JJ5
Fidler, IJ.6
-
75
-
-
0037386774
-
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase
-
Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res. 2003; 9:1546-1556.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1546-1556
-
-
Ciardiello, F1
Caputo, R2
Damiano, V3
Caputo, R4
Troiani, T5
Vitagliano, D6
Carlomagno, F7
Veneziani, BM8
Fontanini, G9
Bianco, AR10
Tortora, G.11
-
76
-
-
84908127948
-
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
-
Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014; 15:1236-1244.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1236-1244
-
-
Seto, T1
Kato, T2
Nishio, M3
Goto, K4
Atagi, S5
Hosomi, Y6
Yamamoto, N7
Hida, T8
Maemondo, M9
Nakagawa, K10
Nagase, S11
Okamoto, I12
Yamanaka, T13
-
77
-
-
84975183505
-
A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial
-
abstr 3BA
-
Stahel RA, Dafni U, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Massutí B, Cardenal F, Aix SP, Früh M, Pless M, Popat S, Kotsakis A, et al. A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. Ann Oncol. 2015; abstr 3BA.
-
(2015)
Ann Oncol
-
-
Stahel, RA1
Dafni, U2
Gautschi, O3
Felip, E4
Curioni-Fontecedro, A5
Peters, S6
Massutí, B7
Cardenal, F8
Aix, SP9
Früh, M10
Pless, M11
Popat, S12
Kotsakis, A13
-
78
-
-
84938275519
-
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001
-
Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, et al. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. J Thorac Ooncol. 2015; 10:486-491.
-
(2015)
J Thorac Ooncol
, vol.10
, pp. 486-491
-
-
Ichihara, E1
Hotta, K2
Nogami, N3
Kuyama, S4
Kishino, D5
Fujii, M6
Kozuki, T7
Tabata, M8
Harada, D9
Chikamori, K10
Aoe, K11
Ueoka, H12
Hosokawa, S13
-
79
-
-
84891656497
-
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer
-
Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013; 31:3926-3934.
-
(2013)
J Clin Oncol
, vol.31
, pp. 3926-3934
-
-
Johnson, BE1
Kabbinavar, F2
Fehrenbacher, L3
Hainsworth, J4
Kasubhai, S5
Kressel, B6
Lin, CY7
Marsland, T8
Patel, T9
Polikoff, J10
Rubin, M11
White, L12
Yang, JC13
-
80
-
-
79957823572
-
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
-
Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011; 377:1846-1854.
-
(2011)
Lancet
, vol.377
, pp. 1846-1854
-
-
Herbst, RS1
Ansari, R2
Bustin, F3
Flynn, P4
Hart, L5
Otterson, GA6
Vlahovic, G7
Soh, CH8
O'Connor, P9
Hainsworth, J.10
-
81
-
-
84942198850
-
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
-
Otsuka K, Hata A, Takeshita J, Okuda C, Kaji R, Masago K, Fujita S, Katakami N. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer. Cancer Chemo and pharmacol. 2015; 76:835-841.
-
(2015)
Cancer Chemo and pharmacol
, vol.76
, pp. 835-841
-
-
Otsuka, K1
Hata, A2
Takeshita, J3
Okuda, C4
Kaji, R5
Masago, K6
Fujita, S7
Katakami, N.8
-
82
-
-
84975498256
-
BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer
-
Gridelli C, Rossi A, Ciardiello F, De Marinis F, Crinò L, Morabito A, Morgillo F, Montanino A, Daniele G, Piccirillo MC, Normanno N, Gallo C, Perrone F. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016; 17:461-465.
-
(2016)
Clin Lung Cancer
, vol.17
, pp. 461-465
-
-
Gridelli, C1
Rossi, A2
Ciardiello, F3
De Marinis, F4
Crinò, L5
Morabito, A6
Morgillo, F7
Montanino, A8
Daniele, G9
Piccirillo, MC10
Normanno, N11
Gallo, C12
Perrone, F.13
-
83
-
-
85007291864
-
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer
-
Garon EB, Reck M, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Lee P, Dalal R, Liu J, He S, Treat J, Nakagawa K. Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer. Clin lung cancer. 2016; 18:96-99.
-
(2016)
Clin lung cancer
, vol.18
, pp. 96-99
-
-
Garon, EB1
Reck, M2
Paz-Ares, L3
Ponce, S4
Jaime, JC5
Juan, O6
Nadal, E7
Lee, P8
Dalal, R9
Liu, J10
He, S11
Treat, J12
Nakagawa, K.13
-
84
-
-
79959306917
-
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer
-
Spigel DR, Burris HA 3rd, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, Bass JD, Hainsworth JD. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29:2582-2589.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2582-2589
-
-
Spigel, DR1
Burris, HA2
Greco, FA3
Shipley, DL4
Friedman, EK5
Waterhouse, DM6
Whorf, RC7
Mitchell, RB8
Daniel, DB9
Zangmeister, J10
Bass, JD11
Hainsworth, JD.12
-
85
-
-
84883360843
-
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic nonsmall-cell lung cancer (NSCLC)
-
Groen HJ, Socinski MA, Grossi F, Juhasz E, Gridelli C, Baas P, Butts CA, Chmielowska E, Usari T, Selaru P, Harmon C, Williams JA, Gao F, et al. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic nonsmall-cell lung cancer (NSCLC). Ann Oncol. 2013; 24:2382-2389.
-
(2013)
Ann Oncol
, vol.24
, pp. 2382-2389
-
-
Groen, HJ1
Socinski, MA2
Grossi, F3
Juhasz, E4
Gridelli, C5
Baas, P6
Butts, CA7
Chmielowska, E8
Usari, T9
Selaru, P10
Harmon, C11
Williams, JA12
Gao, F13
-
86
-
-
84863936062
-
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial
-
Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, Wierzbicki RF, Albert I, Thomas M, Miziara JE, Papai ZS, Karaseva N, Thongprasert S, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol. 2012; 30:2070-2078.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2070-2078
-
-
Scagliotti, GV1
Krzakowski, M2
Szczesna, A3
Strausz, J4
Makhson, A5
Reck, M6
Wierzbicki, RF7
Albert, I8
Thomas, M9
Miziara, JE10
Papai, ZS11
Karaseva, N12
Thongprasert, S13
-
87
-
-
85101803225
-
Icotinib and rh-endostatin as first line therapy in advanced non small cell line cancer patients harboring activating epidermal growth factor receptor mutations
-
abstr e20074
-
Zhao Q, Peng L, Chen F, Hong Z, Mou H, Wang Y, Tang Y, Liu J. Icotinib and rh-endostatin as first line therapy in advanced non small cell line cancer patients harboring activating epidermal growth factor receptor mutations. J Clin Oncol. 2016; abstr e20074.
-
(2016)
J Clin Oncol
-
-
Zhao, Q1
Peng, L2
Chen, F3
Hong, Z4
Mou, H5
Wang, Y6
Tang, Y7
Liu, J.8
-
88
-
-
84944937210
-
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
-
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373:1627-1639.
-
(2015)
N Engl J Med
, vol.373
, pp. 1627-1639
-
-
Borghaei, H1
Paz-Ares, L2
Horn, L3
Spigel, DR4
Steins, M5
Ready, NE6
Chow, LQ7
Vokes, EE8
Felip, E9
Holgado, E10
Barlesi, F11
Kohlhäufl, M12
Arrieta, O13
-
89
-
-
84936791837
-
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
-
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373:123-135.
-
(2015)
N Engl J Med
, vol.373
, pp. 123-135
-
-
Brahmer, J1
Reckamp, KL2
Baas, P3
Crinò, L4
Eberhardt, WE5
Poddubskaya, E6
Antonia, S7
Pluzanski, A8
Vokes, EE9
Holgado, E10
Waterhouse, D11
Ready, N12
Gainor, J13
-
90
-
-
84950117835
-
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
-
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387:1540-1550.
-
(2016)
Lancet
, vol.387
, pp. 1540-1550
-
-
Herbst, RS1
Baas, P2
Kim, DW3
Felip, E4
Pérez-Gracia, JL5
Han, JY6
Molina, J7
Kim, JH8
Arvis, CD9
Ahn, MJ10
Majem, M11
Fidler, MJ12
de Castro, G13
-
91
-
-
84962038946
-
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
-
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016; 387:1837-1846.
-
(2016)
Lancet
, vol.387
, pp. 1837-1846
-
-
Fehrenbacher, L1
Spira, A2
Ballinger, M3
Kowanetz, M4
Vansteenkiste, J5
Mazieres, J6
Park, K7
Smith, D8
Artal-Cortes, A9
Lewanski, C10
Braiteh, F11
Waterkamp, D12
He, P13
-
92
-
-
84994802263
-
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
-
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375:1823-1833.
-
(2016)
N Engl J Med
, vol.375
, pp. 1823-1833
-
-
Reck, M1
Rodríguez-Abreu, D2
Robinson, AG3
Hui, R4
Csőszi, T5
Fülöp, A6
Gottfried, M7
Peled, N8
Tafreshi, A9
Cuffe, S10
O'Brien, M11
Rao, S12
Hotta, K13
-
93
-
-
84876717683
-
Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo
-
Yasuda S, Sho M, Yamato I, Yoshiji H, Wakatsuki K, Nishiwada S, Yagita H, Nakajima Y. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol. 2013; 172:500-506.
-
(2013)
Clin Exp Immunol
, vol.172
, pp. 500-506
-
-
Yasuda, S1
Sho, M2
Yamato, I3
Yoshiji, H4
Wakatsuki, K5
Nishiwada, S6
Yagita, H7
Nakajima, Y.8
-
94
-
-
85015304170
-
The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC
-
Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crino L, Felip E, Fennell D, Garrido P, et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol. 2016; 12:194-207.
-
(2016)
J Thorac Oncol
, vol.12
, pp. 194-207
-
-
Manegold, C1
Dingemans, AC2
Gray, JE3
Nakagawa, K4
Nicolson, M5
Peters, S6
Reck, M7
Wu, YL8
Brustugun, OT9
Crino, L10
Felip, E11
Fennell, D12
Garrido, P13
-
95
-
-
84922713971
-
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
-
Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N, Tanchot C, Stockmann C, Combe P, Berger A, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015; 212:139-148.
-
(2015)
J Exp Med
, vol.212
, pp. 139-148
-
-
Voron, T1
Colussi, O2
Marcheteau, E3
Pernot, S4
Nizard, M5
Pointet, AL6
Latreche, S7
Bergaya, S8
Benhamouda, N9
Tanchot, C10
Stockmann, C11
Combe, P12
Berger, A13
-
96
-
-
84991455944
-
Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines
-
Farsaci B, Donahue RN, Coplin MA, Grenga I, Lepone LM, Molinolo AA, Hodge JW. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol Res. 2014; 2:1090-1102.
-
(2014)
Cancer Immunol Res
, vol.2
, pp. 1090-1102
-
-
Farsaci, B1
Donahue, RN2
Coplin, MA3
Grenga, I4
Lepone, LM5
Molinolo, AA6
Hodge, JW.7
-
97
-
-
33845343558
-
Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy
-
Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res. 2006; 12:6808-6816.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6808-6816
-
-
Li, B1
Lalani, AS2
Harding, TC3
Luan, B4
Koprivnikar, K5
Huan Tu, G6
Prell, R7
VanRoey, MJ8
Simmons, AD9
Jooss, K.10
-
98
-
-
84946240266
-
Nivolumab (Anti-PD-1; BMS-936558, ONO- 4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy
-
Rizvi NA, Antonia SJ, Shepherd FA, Chow LQ, Goldman J, Shen Y, Chen AC, Getting S. Nivolumab (Anti-PD-1; BMS-936558, ONO- 4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy. Radiation Oncol. 2014; 90:S32.
-
(2014)
Radiation Oncol
, vol.90
, pp. S32
-
-
Rizvi, NA1
Antonia, SJ2
Shepherd, FA3
Chow, LQ4
Goldman, J5
Shen, Y6
Chen, AC7
Getting, S.8
-
99
-
-
84964313298
-
Bevacizumab plus ipilimumab in patients with metastatic melanoma
-
Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014; 2:632-642.
-
(2014)
Cancer Immunol Res
, vol.2
, pp. 632-642
-
-
Hodi, FS1
Lawrence, D2
Lezcano, C3
Wu, X4
Zhou, J5
Sasada, T6
Zeng, W7
Giobbie-Hurder, A8
Atkins, MB9
Ibrahim, N10
Friedlander, P11
Flaherty, KT12
Murphy, GF13
-
100
-
-
84949959569
-
Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC)
-
abstr 410
-
Sznol M, McDermott DF, Jones SF, Mier JW, Waterkamp D, Rossi C, Wallin J, Funke RP, Bendell JC. Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2015; abstr 410.
-
(2015)
J Clin Oncol
-
-
Sznol, M1
McDermott, DF2
Jones, SF3
Mier, JW4
Waterkamp, D5
Rossi, C6
Wallin, J7
Funke, RP8
Bendell, JC.9
-
101
-
-
84962497081
-
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
-
McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fassò M, Wang YV, Zou W, Hegde PS, Fine GD, Powles T. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. J Clin Oncol. 2016; 34:833-42.
-
(2016)
J Clin Oncol
, vol.34
, pp. 833-842
-
-
McDermott, DF1
Sosman, JA2
Sznol, M3
Massard, C4
Gordon, MS5
Hamid, O6
Powderly, JD7
Infante, JR8
Fassò, M9
Wang, YV10
Zou, W11
Hegde, PS12
Fine, GD13
Powles, T.14
-
102
-
-
0042343801
-
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
-
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
-
(2003)
N Engl J Med
, vol.349
, pp. 427-434
-
-
Yang, JC1
Haworth, L2
Sherry, RM3
Hwu, P4
Schwartzentruber, DJ5
Topalian, SL6
Steinberg, SM7
Chen, HX8
Rosenberg, SA.9
-
103
-
-
84949950400
-
Safety and efficacy of MPDL3280A (anti- PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC)
-
abstr 704
-
Bendell JC, Powderly JD, Lieu CH, Eckhardt SG, Hurwitz H, Hochster HS, Murphy JE, Funke RP, Rossi C, Wallin J, Waterkamp D, Pishvaian MJ. Safety and efficacy of MPDL3280A (anti- PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2015; abstr 704.
-
(2015)
J Clin Oncol
-
-
Bendell, JC1
Powderly, JD2
Lieu, CH3
Eckhardt, SG4
Hurwitz, H5
Hochster, HS6
Murphy, JE7
Funke, RP8
Rossi, C9
Wallin, J10
Waterkamp, D11
Pishvaian, MJ.12
-
104
-
-
85013118657
-
A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, nonsmall cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results
-
abstr 3056
-
Herbst RS, Bendell JC, Isambert N, Calvo E, Santana-Davila R, Cassier P, Perez-Gracia JL, Yang J, Rege J, Ferry D, Mi G, Chau I. A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, nonsmall cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. J Clin Oncol. 2016; abstr 3056.
-
(2016)
J Clin Oncol
-
-
Herbst, RS1
Bendell, JC2
Isambert, N3
Calvo, E4
Santana-Davila, R5
Cassier, P6
Perez-Gracia, JL7
Yang, J8
Rege, J9
Ferry, D10
Mi, G11
Chau, I.12
-
105
-
-
84914176528
-
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)
-
abstr 5010
-
Amin A, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, Knox JJ, Pal SK, Voss MH, Sharma P, Kollmannsberger CK, Heng DYC, Spratlin JL, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2014; abstr 5010.
-
(2014)
J Clin Oncol
-
-
Amin, A1
Plimack, ER2
Infante, JR3
Ernstoff, MS4
Rini, BI5
McDermott, DF6
Knox, JJ7
Pal, SK8
Voss, MH9
Sharma, P10
Kollmannsberger, CK11
Heng, DYC12
Spratlin, JL13
-
106
-
-
77649213706
-
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2
-
Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010; 28:780-7.
-
(2010)
J Clin Oncol
, vol.28
, pp. 780-787
-
-
Spratlin, JL1
Cohen, RB2
Eadens, M3
Gore, L4
Camidge, DR5
Diab, S6
Leong, S7
O'Bryant, C8
Chow, LQ9
Serkova, NJ10
Meropol, NJ11
Lewis, NL12
Chiorean, EG13
-
107
-
-
84947943267
-
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
-
Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhász E, Arén O, Sun Y, Schmelter T, et al. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. J Thorac Oncol. 2015; 10:1745-1753.
-
(2015)
J Thorac Oncol
, vol.10
, pp. 1745-1753
-
-
Paz-Ares, L1
Hirsh, V2
Zhang, L3
de Marinis, F4
Yang, JC5
Wakelee, HA6
Seto, T7
Wu, YL8
Novello, S9
Juhász, E10
Arén, O11
Sun, Y12
Schmelter, T13
-
108
-
-
84861720010
-
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)
-
Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2012; 30:1114-1121.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1114-1121
-
-
Lee, JS1
Hirsh, V2
Park, K3
Qin, S4
Blajman, CR5
Perng, RP6
Chen, YM7
Emerson, L8
Langmuir, P9
Manegold, C.10
-
109
-
-
84894244012
-
A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805)
-
Zhou Q, Zhou CC, Chen GY, Cheng Y, Huang C, Zhang L, Xu CR, Li AW, Yan HH, Su J, Zhang XC, Yang JJ, Wu YL. A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). Lung cancer. 2014; 83:369-373.
-
(2014)
Lung cancer
, vol.83
, pp. 369-373
-
-
Zhou, Q1
Zhou, CC2
Chen, GY3
Cheng, Y4
Huang, C5
Zhang, L6
Xu, CR7
Li, AW8
Yan, HH9
Su, J10
Zhang, XC11
Yang, JJ12
Wu, YL.13
-
110
-
-
70349304196
-
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer
-
Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27:4274-4280.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4274-4280
-
-
Blumenschein, GR1
Gatzemeier, U2
Fossella, F3
Stewart, DJ4
Cupit, L5
Cihon, F6
O'Leary, J7
Reck, M.8
-
111
-
-
84866625336
-
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501
-
Wakelee HA, Lee JW, Hanna NH, Traynor AM, Carbone DP, Schiller JH. A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. J Thorac Oncol. 2012; 7:1574-1582.
-
(2012)
J Thorac Oncol
, vol.7
, pp. 1574-1582
-
-
Wakelee, HA1
Lee, JW2
Hanna, NH3
Traynor, AM4
Carbone, DP5
Schiller, JH.6
-
112
-
-
79952748468
-
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer
-
Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29:1059-1066.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1059-1066
-
-
Natale, RB1
Thongprasert, S2
Greco, FA3
Thomas, M4
Tsai, CM5
Sunpaweravong, P6
Ferry, D7
Mulatero, C8
Whorf, R9
Thompson, J10
Barlesi, F11
Langmuir, P12
Gogov, S13
-
113
-
-
79957452054
-
A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
-
Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P, von Pawel J. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol. 2011; 22:1374-1381.
-
(2011)
Ann Oncol
, vol.22
, pp. 1374-1381
-
-
Reck, M1
Kaiser, R2
Eschbach, C3
Stefanic, M4
Love, J5
Gatzemeier, U6
Stopfer, P7
von Pawel, J.8
-
114
-
-
80051801904
-
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer
-
Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, et al. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011; 6:1418-1425.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1418-1425
-
-
Tan, EH1
Goss, GD2
Salgia, R3
Besse, B4
Gandara, DR5
Hanna, NH6
Yang, JC7
Thertulien, R8
Wertheim, M9
Mazieres, J10
Hensing, T11
Lee, C12
Gupta, N13
-
115
-
-
84892808887
-
A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens
-
abstr 7548
-
Zhang L, Shi M, Huang C, Liu X, Xiong J, Chen G, Liu W, Liu W, Zhang Y, Li K, Yu H, Jiang H. A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens. J Clin Oncol. 2012; abstr 7548.
-
(2012)
J Clin Oncol
-
-
Zhang, L1
Shi, M2
Huang, C3
Liu, X4
Xiong, J5
Chen, G6
Liu, W7
Liu, W8
Zhang, Y9
Li, K10
Yu, H11
Jiang, H.12
-
116
-
-
84950120863
-
Anti-angiogenesis in personalized therapy of lung cancer
-
Ellis PM. Anti-angiogenesis in personalized therapy of lung cancer. Adv Exp Med Biol. 2016; 893:91-126.
-
(2016)
Adv Exp Med Biol
, vol.893
, pp. 91-126
-
-
Ellis, PM.1
-
117
-
-
84947966922
-
New antiangiogenetic therapy beyond bevacizumab in the treatment of advanced non small cell lung cancer
-
Sacco PC, Maione P, Rossi A, Sgambato A, Casaluce F, Palazzolo G, Gridelli C. New antiangiogenetic therapy beyond bevacizumab in the treatment of advanced non small cell lung cancer. Curr Pharm Des. 2015; 21:4763-4772.
-
(2015)
Curr Pharm Des
, vol.21
, pp. 4763-4772
-
-
Sacco, PC1
Maione, P2
Rossi, A3
Sgambato, A4
Casaluce, F5
Palazzolo, G6
Gridelli, C.7
|